{
    "nct_id": "NCT06679985",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2024-11-08",
    "study_start_date": "2024-12-20",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Casdozokitug"
            },
            {
                "drug_name": "Drug: Bevacizumab"
            },
            {
                "drug_name": "Drug: Toripalimab"
            }
        ]
    },
    "long_title": "A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma",
    "last_updated": "2025-08-24",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE2",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Coherus Biosciences, Inc.",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 72,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Key Inclusion Criteria:",
        "* Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants.",
        "* Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies.",
        "* \u2265 1 measurable lesion (per RECIST v1.1) that is untreated.",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Has received prior systemic therapy for HCC.",
        "Exclude - * Has previously received an anti-IL-27 antibody (Ab) or anti-IL-27-targeted therapy.",
        "Exclude - * Has known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.",
        "Exclude - * Has moderate or severe ascites.",
        "Exclude - * Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).",
        "Exclude - Additional protocol-defined inclusion/exclusion criteria apply."
    ],
    "short_title": "A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Coherus Biosciences, Inc.",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Arm A: Casdozokitug Lower Dose + Toripalimab + Bevacizumab",
                        "arm_internal_id": 0,
                        "arm_description": "Arm A: Casdozokitug Lower Dose + Toripalimab + Bevacizumab",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Casdozokitug",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Toripalimab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Bevacizumab",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm B: Casdozokitug Higher dose + Toripalimab + Bevacizumab",
                        "arm_internal_id": 1,
                        "arm_description": "Arm B: Casdozokitug Higher dose + Toripalimab + Bevacizumab",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Casdozokitug",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Toripalimab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Bevacizumab",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Arm C: Toripalimab + Bevacizumab",
                        "arm_internal_id": 2,
                        "arm_description": "Arm C: Toripalimab + Bevacizumab",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Toripalimab",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Bevacizumab",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Hepatocellular Carcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Fibrolamellar Carcinoma"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Unresectable",
                                        "Locally Advanced",
                                        "Metastatic",
                                        "Untreated"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}